Results 11 to 20 of about 24,145,261 (292)
Hematological Oncology, 2023 Abstract Large B‐cell lymphoma, the prototype of aggressive non‐Hodgkin lymphomas, is both the most common lymphoma and accounts for the highest global burden of lymphoma‐related deaths. For nearly 4 decades, the goal of treatment has been “cure”, first based on CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), and ...
Barraclough, Allison +3 more
openaire +3 more sources
Identification and validation of 5-methylcytosine-associated genes in diffuse large B-cell lymphoma
Heliyon, 2023 5-methylcytosine modifications play a significant role in carcinogenesis; however, studies exploring 5-methylcytosine-related genes in diffuse large B-cell lymphoma patients are lacking.
Cheng Xing +14 more
doaj +1 more source
The impact of molecular alterations and the immune microenvironment on the natural history of Follicular Lymphoma including transformation to Diffuse Large B cell Lymphoma [PDF]
, 2009 PhDThe natural history of follicular lymphoma is heterogeneous with numerous relapses and remissions over many years. A substantial number of patients suffer an aggressive disease course with death due to disease within 5 years of diagnosis.
Lee, Abigail Mary
core +4 more sources
Heliyon, 2023 Diffuse large B-cell lymphoma (DLBCL) is a highly aggressive B-lymphocyte-derived malignant proliferative disease that is currently one of the leading causes of death in HIV patients.
Tao Peng fei, Hui Ru Xi, Min Hai yan
doaj +1 more source
Genetics of diffuse large B-cell lymphoma [PDF]
Blood, 2018 Abstract Diffuse large B-cell lymphoma (DLBCL), the most frequent subtype of lymphoid malignancy, remains a significant clinical challenge, as ∼30% of patients are not cured. Over the past decade, remarkable progress has been made in the understanding of the pathogenesis of this disease, spurred by the implementation of powerful ...
Pasqualucci, Laura +1 more
openaire +7 more sources
Intravascular diffuse large B-cell lymphoma with acquired ichthyosis: A case report
SAGE Open Medical Case Reports, 2023 Intravascular diffuse large B-cell lymphoma is an exceedingly rare subtype of B-cell lymphomas. This cancer is often associated with poor prognosis and can be lethal if left untreated.
Zainab Ridha +3 more
doaj +1 more source
Haematologica, 2010 Background Multiparameter flow cytometry allows the detection of minor monoclonal B-cell populations. Using this technique combined with morphology, we were struck by the presence of minor populations of small monoclonal B cells in bone marrows of ...
Anne M. Tierens +6 more
doaj +1 more source
Journal of Medical Case Reports, 2020 Background Epstein-Barr virus is associated with many human hematopoietic neoplasms; however, Epstein-Barr virus-positive mucosa-associated lymphoid tissue lymphoma is extremely rare.
Vadim R. Gorodetskiy +6 more
doaj +1 more source
Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs
Haematologica, 2017 Histone methylation and demethylation regulate B-cell development, and their deregulation correlates with tumor chemoresistance in diffuse large B-cell lymphoma, limiting cure rates. Since histone methylation status correlates with disease aggressiveness
Rohit Mathur +9 more
doaj +1 more source
Lenalidomide in Diffuse Large B-Cell Lymphomas [PDF]
Advances in Hematology, 2012 Diffuse Large B-cell Lymphomas (DLBCL) are the most frequent Non-Hodgkin Lymphomas (NHL). The addition of Rituximab to the standard chemotherapy CHOP improved the outcome in this patients, but so far 40% of patients experienced relapse or progressive disease.
Annalisa Chiappella, Umberto Vitolo
openaire +3 more sources